Home › Funds › PENN SERIES FUNDS INC › Small Cap Growth Fund
Fund family: PENN SERIES FUNDS INC · Filed by PENN SERIES FUNDS INC (CIK 702340) · SEC series S000006737
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 1,032 with, 8 against, 0 abstentions (not counted as with management); 3 items carried no recommendation. Shareholder proposals: 5 FOR, 4 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as PENN SERIES FUNDS INC’s manager page (42,846 ballot items across 19 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | PENN SERIES FUNDS INC | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 94.9% | 994 | 93.7% | 37,596 |
| Backed environmental and social shareholder proposals at US companies | n/a | 1 | 10.0% | 422 |
Each ballot item this fund voted is set against the votes of the other PENN SERIES FUNDS INC funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most PENN SERIES FUNDS INC funds on 3 items (2.2% of the 135 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most PENN SERIES FUNDS INC funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Globus Medical, Inc. | 2026-06-03 | Approval of an amendment to the Globus Medical, Inc. 2021 Equity Incentive Plan to increase the number of authorized shares thereunder by 1,000,000. | For | AGAINST — 4 of 4 PENN SERIES FUNDS INC funds | For | Approved, 76.6% support |
| Revolution Medicines, Inc. | 2026-06-18 | To elect two Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until his successor is elected: Alexis Borisy | Withhold | FOR — 2 of 3 PENN SERIES FUNDS INC funds | Against | Passed (calculated), 79.1% support |
| Praxis Precision Medicines, Inc. | 2026-06-10 | To elect the Class III Directors to serve until the 2029 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified: William Young | For | WITHHOLD — 2 of 3 PENN SERIES FUNDS INC funds | For | Passed (calculated), 85.5% support |
Download all 3 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 81.1% of this fund’s 1,040 such votes could be given a sector; the other 197 (18.9%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 225 | 1 | 0.4% |
| Industrials | 181 | 1 | 0.6% |
| Consumer Discretionary | 135 | 1 | 0.7% |
| Technology | 110 | 0 | 0.0% |
| Finance | 94 | 1 | 1.1% |
| Real Estate | 26 | 0 | 0.0% |
| Energy | 21 | 0 | 0.0% |
| Miscellaneous | 16 | 0 | 0.0% |
| Telecommunications | 14 | 0 | 0.0% |
| Utilities | 14 | 1 | 7.1% |
| Consumer Staples | 7 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 689 | 0 |
| Audit-related | 125 | 0 |
| Say-on-Pay | 111 | 0 |
| Compensation | 49 | 0 |
| Corporate Governance | 40 | 7 |
| Capital Structure | 16 | 0 |
| Extraordinary Transactions | 14 | 0 |
| Shareholder Rights and Defenses | 5 | 0 |
| Other | 2 | 0 |
| Environment or Climate | 1 | 1 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Glaukos Corporation | May 28, 2026 | $4M | 4 | 0 |
| Casey's General Stores, Inc. | September 3, 2025 | $2M | 15 | 1 |
| Ligand Pharmaceuticals Incorporated | June 5, 2026 | $2M | 11 | 0 |
| SS&C Technologies Holdings, Inc. | May 20, 2026 | $2M | 6 | 0 |
| Crown Holdings, Inc. | April 30, 2026 | $2M | 13 | 1 |
| Cboe Global Markets, Inc. | May 14, 2026 | $2M | 15 | 1 |
| Sensient Technologies Corporation | April 23, 2026 | $2M | 11 | 0 |
| OSI Systems, Inc. | December 11, 2025 | $2M | 8 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| September 3, 2025 | Casey's General Stores, Inc. | Shareholder proposal regarding Scope 3 greenhouse gas reduction targets. Shareholder proposal | Against | For |
| April 30, 2026 | Crown Holdings, Inc. | Consideration of a Shareholder proposal regarding Shareholder right to act by written consent. Shareholder proposal | For | Against |
| May 14, 2026 | Cboe Global Markets, Inc. | Stockholder proposal regarding shareholder right to act by written consent. Shareholder proposal | For | Against |
| May 13, 2026 | ICU Medical, Inc. | To approve, on an advisory basis, a stockholder proposal to establish a 10% stockholder special meeting right. Shareholder proposal | Against | For |
| April 30, 2026 | NRG Energy, Inc. | To vote on a stockholder proposal to give shareholders the ability to call for a special shareholder meeting, if properly presented at the meeting. Shareholder proposal | For | Against |
| May 6, 2026 | Entegris, Inc. | Stockholder Proposal: Providing stockholders the right to call special meetings of stockholders. Shareholder proposal | For | Against |
| May 6, 2026 | Premium Brands Holdings Corporation | SP 1: Adopt and Disclose Policy to Review and Disclose Findings for Directors With Low Vote Support Shareholder proposal | Against | For |
| May 6, 2026 | Premium Brands Holdings Corporation | SP 2: Adopt and Disclose Policy to Regularly Disclose Director Voting Records Shareholder proposal | Against | For |
Meetings with a proxy contest or competing nominees (2 in 2025-2026), and how the fund voted the items on its ballot.
1,053 ballot items at 129 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Small Cap Growth Fund voted at 129 shareholder meetings of 125 companies, on 1,053 ballot items in all. Where management made a recommendation, the fund followed it on 99.2% of the items and voted against it 8 times. Its most frequent area of disagreement was corporate governance (7 of its votes against management). It voted on 9 shareholder proposals. It voted FOR the board's own proposals more often than PENN SERIES FUNDS INC's funds as a whole (94.9% against 93.7%). It voted differently from most PENN SERIES FUNDS INC funds on 3 items. 2 of its meetings were contested.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of PENN SERIES FUNDS INC’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.